AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
Inc. (the Company) of his intention to resign as President and
Chief Operating Officer of the Company. Mr. Thomas has agreed to
stay with the Company through April 30, 2017 to assist with
transition matters, at which time William K. Heiden, the Companys
Chief Executive Officer, will assume the title of President.
Officer and as a member of the Companys board of directors since
May 2012, and previously served as President from May 2012 through
April 2015. Mr. Heiden has held a variety of senior executive roles
in the life sciences industry over the last 30 years, additional
details of which can be found on page 10 in the Company’s proxy
statement filed with the SEC on April 15, 2016. He has served as
president and chief executive officer of several local public and
private biotechnology companies, after having served in a variety
of global general management positions over a 15 year career with
Schering Plough/Merck. Mr. Heiden does not have any family
relationships with any of the Companys directors or executive
officers and is not a party to any transactions listed in Item
404(a) of Regulation S-K.
not be deemed filed for purposes of Section 18 of the Exchange Act,
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act, except as expressly set forth by specific reference
in such filing.
furnished as Exhibit 99.1 to this report.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press Release dated March 6, 2017
|
About AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Recent Trading Information
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) closed its last trading session 00.00 at 23.10 with 656,442 shares trading hands.
